Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma

Fineline Cube Jul 23, 2026
Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Fineline Cube Jul 22, 2026
Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Fineline Cube Jul 22, 2026
Company Deals

Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody

Fineline Cube Jul 22, 2026
Company Deals

Grand Pharma Partners with Siemens Healthineers to Commercialize AcuNav Lumos 4D ICE Catheter in China’s Structural Heart Market

Fineline Cube Jul 21, 2026
Policy / Regulatory

Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring

Fineline Cube Jul 23, 2026
Company Drug

CSPC Pharmaceutical Launches Phase 2 Trial of SYS 6026 mRNA Vaccine for HPV-Related Cervical Precancer

Fineline Cube Jul 23, 2026
Company Drug

PegBio Launches Commercial Prescriptions for Paidakang GLP-1RA in China, Triggers Milestone Payments

Fineline Cube Jul 23, 2026
Company Deals

J&J’s Janssen Secures Exclusive Global Rights to Develop LCB84 ADC from LegoChem Biosciences

Fineline Cube Dec 27, 2023

Johnson & Johnson’s (J&J; NYSE: JNJ) pharmaceutical subsidiary, Janssen, has entered into an exclusive global...

Company Deals

BMS Expands Oncology Portfolio with $4.1 Billion RayzeBio Acquisition

Fineline Cube Dec 27, 2023

Bristol Myers Squibb (BMS; NYSE: BMY) has announced the acquisition of RayzeBio (NASDAQ: RYZB), a...

Company Drug

Amgen’s Lumakras Faces Full Approval Delay as FDA Requests New Study

Fineline Cube Dec 27, 2023

The US Food and Drug Administration (FDA) has declined to grant full approval for Amgen’s...

Policy / Regulatory

China’s NMPA Proposes Enhanced IT and Visualization Requirements for Blood Product GMP

Fineline Cube Dec 27, 2023

The National Medical Products Administration (NMPA) of China is currently soliciting public feedback on the...

Company Medical Device

Fresenius Medical Care Expands Dialysis Solutions in China with 6008 CARESystem Launch

Fineline Cube Dec 27, 2023

Fresenius Medical Care AG has announced the official launch of its 6008 CARESystem hemodialysis filtration...

Policy / Regulatory

China Charts Course for Advanced Disease Prevention and Control System by 2030

Fineline Cube Dec 27, 2023

China’s State Council has issued the “Guiding Opinions on Promoting the High Quality Development of...

Company Deals

Innovent Biologics Partners with Sanegene Bio USA to Develop Hypertension Drug

Fineline Cube Dec 27, 2023

China-based Innovent Biologics (HKG: 1801) has entered into a partnership with Sanegene Bio USA Inc....

Company Drug

Guangdong Zhongsheng Pharmaceutical’s ZSP1273 for Influenza A Accepted for Review by NMPA

Fineline Cube Dec 27, 2023

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a Chinese pharmaceutical company, has announced that China’s...

Company Drug

Konruns Pharmaceutical Receives NMPA Go-Ahead for KC1036 Esophageal Cancer Study

Fineline Cube Dec 27, 2023

Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has received approval from the National Medical Products...

Company Deals

Jianzhijia Health-Chain to Purchase Local Drug Retailer for $23.5 Million

Fineline Cube Dec 27, 2023

Yunnan Jianzhijia Health-Chain Co, Ltd (SHA: 605266), a Chinese healthcare company, has announced plans to...

Company Drug

Simcere Affiliate Shanghai Simnova Biotech Gets China Nod for CAR-T Therapy SNC109

Fineline Cube Dec 27, 2023

Shanghai Simnova Biotech Co., Ltd, known as Simnova outside of China and an affiliate of...

Company Deals

Biocytogen and Lepu Biotechnology Develop WT1-Targeted Trispecific Antibody for Cancer Treatment

Fineline Cube Dec 27, 2023

Biocytogen Pharmaceuticals (Beijing) Co., Ltd, (HKG: 2315) and Lepu Biotechnology Co., Ltd (HKG: 2157) have...

Company Deals

Aidea Pharmaceutical Co. Terminates ACC006 Technology Transfer Deal with Lixin Bio

Fineline Cube Dec 27, 2023

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has resolved to terminate its technology transfer agreement...

Company Deals

AstraZeneca to Acquire China’s Gracell Biotechnologies in $1.2 Billion Deal

Fineline Cube Dec 26, 2023

Pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has announced its intention to fully acquire Gracell Biotechnologies...

Policy / Regulatory

China’s NHC Releases Third List of Recommended Generic Drugs for Development

Fineline Cube Dec 26, 2023

The National Health Commission (NHC) of China has released its third list of drugs recommended...

Company Drug

FDA Grants Priority Review to MSD and Daiichi Sankyo’s ADC for Lung Cancer

Fineline Cube Dec 26, 2023

The US Food and Drug Administration (FDA) has accepted under priority review a filing from...

Company Deals Drug

AbbVie and Alpine Immune Sciences Halt Early Enrollment in Lupus Trial

Fineline Cube Dec 26, 2023

AbbVie (NYSE: ABBV) and Alpine Immune Sciences (SWX: ALPN) have made the decision to prematurely...

Policy / Regulatory

Jiangsu Province Announces Dual Channel Management and Separate Payment Drug List

Fineline Cube Dec 26, 2023

Jiangsu province’s healthcare security administration has released a list identifying drugs subject to dual channel...

Company Drug

J&J’s Rybrevant-Lazertinib Combo Accepted for FDA Review in NSCLC

Fineline Cube Dec 26, 2023

The US Food and Drug Administration (FDA) has accepted for review Johnson & Johnson’s (J&J;...

Policy / Regulatory

Hunan Province Releases “Dual Channel” Drug Payment List with 226 Products

Fineline Cube Dec 26, 2023

The Hunan Healthcare Security Administration has published a list of 226 drugs to be included...

Posts pagination

1 … 457 458 459 … 699

Recent updates

  • MicroPort MedBot Achieves First-Ever Semi-Annual Profit on 200-230% Revenue Surge
  • CSPC Pharmaceutical Launches Phase 2 Trial of SYS 6026 mRNA Vaccine for HPV-Related Cervical Precancer
  • PegBio Launches Commercial Prescriptions for Paidakang GLP-1RA in China, Triggers Milestone Payments
  • Sino Biopharmaceutical Subsidiary Secures NMPA Approval for IM-101 Therapeutic Vaccine in Chronic Hepatitis B
  • OrbusNeich Enrolls First Patient in Pivotal Japanese Trial for Proprietary Drug-Coated Balloon
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

MicroPort MedBot Achieves First-Ever Semi-Annual Profit on 200-230% Revenue Surge

Company Drug

CSPC Pharmaceutical Launches Phase 2 Trial of SYS 6026 mRNA Vaccine for HPV-Related Cervical Precancer

Company Drug

PegBio Launches Commercial Prescriptions for Paidakang GLP-1RA in China, Triggers Milestone Payments

Company Drug

Sino Biopharmaceutical Subsidiary Secures NMPA Approval for IM-101 Therapeutic Vaccine in Chronic Hepatitis B

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.